DVAX vs. IRWD, LGND, GERN, MNKD, PRTA, INVA, OPK, LXRX, URGN, and PBYI
Should you be buying Dynavax Technologies stock or one of its competitors? The main competitors of Dynavax Technologies include Ironwood Pharmaceuticals (IRWD), Ligand Pharmaceuticals (LGND), Geron (GERN), MannKind (MNKD), Prothena (PRTA), Innoviva (INVA), OPKO Health (OPK), Lexicon Pharmaceuticals (LXRX), UroGen Pharma (URGN), and Puma Biotechnology (PBYI). These companies are all part of the "pharmaceutical preparations" industry.
Dynavax Technologies (NASDAQ:DVAX) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, community ranking, risk, earnings and media sentiment.
Dynavax Technologies presently has a consensus target price of $25.00, suggesting a potential upside of 112.95%. Ironwood Pharmaceuticals has a consensus target price of $19.80, suggesting a potential upside of 143.84%. Given Ironwood Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than Dynavax Technologies.
Dynavax Technologies has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.
In the previous week, Ironwood Pharmaceuticals had 10 more articles in the media than Dynavax Technologies. MarketBeat recorded 12 mentions for Ironwood Pharmaceuticals and 2 mentions for Dynavax Technologies. Ironwood Pharmaceuticals' average media sentiment score of 0.59 beat Dynavax Technologies' score of 0.00 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.
Dynavax Technologies has higher earnings, but lower revenue than Ironwood Pharmaceuticals. Dynavax Technologies is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
97.0% of Dynavax Technologies shares are owned by institutional investors. 3.0% of Dynavax Technologies shares are owned by insiders. Comparatively, 13.1% of Ironwood Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Dynavax Technologies has a net margin of -2.75% compared to Ironwood Pharmaceuticals' net margin of -226.37%. Dynavax Technologies' return on equity of -1.08% beat Ironwood Pharmaceuticals' return on equity.
Ironwood Pharmaceuticals received 38 more outperform votes than Dynavax Technologies when rated by MarketBeat users. However, 65.77% of users gave Dynavax Technologies an outperform vote while only 61.04% of users gave Ironwood Pharmaceuticals an outperform vote.
Summary
Ironwood Pharmaceuticals beats Dynavax Technologies on 10 of the 18 factors compared between the two stocks.
Get Dynavax Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dynavax Technologies Competitors List
Related Companies and Tools
